JP2006504710A - １０，１１−ジヒドロ−１０−ヒドロキシ−５Ｈ−ジベンズ［ｂ，ｆ］アゼピン−５−カルボキサミドの両エナンチオマーのエナンチオ選択的製造方法およびその新規結晶形 - Google Patents

１０，１１−ジヒドロ−１０−ヒドロキシ−５Ｈ−ジベンズ［ｂ，ｆ］アゼピン−５−カルボキサミドの両エナンチオマーのエナンチオ選択的製造方法およびその新規結晶形 Download PDF

Info

Publication number
JP2006504710A
JP2006504710A JP2004540788A JP2004540788A JP2006504710A JP 2006504710 A JP2006504710 A JP 2006504710A JP 2004540788 A JP2004540788 A JP 2004540788A JP 2004540788 A JP2004540788 A JP 2004540788A JP 2006504710 A JP2006504710 A JP 2006504710A
Authority
JP
Japan
Prior art keywords
azepine
hydroxy
dihydro
carboxamide
dibenz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004540788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006504710A5 (cg-RX-API-DMAC10.html
Inventor
クリスティアン・マテス
ゴットフリート・ゼーデルマイヤー
フリッツ・ブラッター
ザビーネ・プフェファー
ドミニク・グリムレ
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2006504710A publication Critical patent/JP2006504710A/ja
Publication of JP2006504710A5 publication Critical patent/JP2006504710A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
    • C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046—Ruthenium compounds
    • C07F15/0053—Ruthenium compounds without a metal-carbon linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2004540788A 2002-10-07 2003-10-06 １０，１１−ジヒドロ−１０−ヒドロキシ−５Ｈ−ジベンズ［ｂ，ｆ］アゼピン−５−カルボキサミドの両エナンチオマーのエナンチオ選択的製造方法およびその新規結晶形 Pending JP2006504710A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223224.7A GB0223224D0 (en) 2002-10-07 2002-10-07 Organic compounds
PCT/EP2003/011034 WO2004031155A1 (en) 2002-10-07 2003-10-06 ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF

Publications (2)

Publication Number Publication Date
JP2006504710A true JP2006504710A (ja) 2006-02-09
JP2006504710A5 JP2006504710A5 (cg-RX-API-DMAC10.html) 2006-11-24

Family

ID=9945425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004540788A Pending JP2006504710A (ja) 2002-10-07 2003-10-06 １０，１１−ジヒドロ−１０−ヒドロキシ−５Ｈ−ジベンズ［ｂ，ｆ］アゼピン−５−カルボキサミドの両エナンチオマーのエナンチオ選択的製造方法およびその新規結晶形

Country Status (20)

Country Link
US (1) US20060142566A1 (cg-RX-API-DMAC10.html)
EP (1) EP1551808A1 (cg-RX-API-DMAC10.html)
JP (1) JP2006504710A (cg-RX-API-DMAC10.html)
KR (1) KR20050071549A (cg-RX-API-DMAC10.html)
CN (2) CN101062932A (cg-RX-API-DMAC10.html)
AR (1) AR041544A1 (cg-RX-API-DMAC10.html)
AU (1) AU2003276055B2 (cg-RX-API-DMAC10.html)
BR (1) BR0315113A (cg-RX-API-DMAC10.html)
CA (1) CA2501237A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP055738A (cg-RX-API-DMAC10.html)
GB (1) GB0223224D0 (cg-RX-API-DMAC10.html)
HK (1) HK1079790A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA05003737A (cg-RX-API-DMAC10.html)
NO (1) NO20052244L (cg-RX-API-DMAC10.html)
PE (1) PE20040686A1 (cg-RX-API-DMAC10.html)
PL (1) PL376379A1 (cg-RX-API-DMAC10.html)
RU (1) RU2005114350A (cg-RX-API-DMAC10.html)
TW (1) TW200413324A (cg-RX-API-DMAC10.html)
WO (1) WO2004031155A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200502561B (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517940A (ja) * 2003-02-17 2006-08-03 ノバルティス アクチエンゲゼルシャフト 神経障害性疼痛におけるｒ−１０−ヒドロキシ−１０，１１−ジヒドロ−カルバマゼピンの使用
JP2016527214A (ja) * 2013-07-01 2016-09-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ケトン類を不斉還元するための新規なルテニウム触媒及びその使用

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0425320D0 (en) 2004-11-17 2004-12-22 Johnson Matthey Plc Diamines
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0515690D0 (en) * 2005-07-29 2005-09-07 Portela & Ca Sa Asymmetric catalytic reduction
GB2437078A (en) * 2006-04-11 2007-10-17 Portela & Ca Sa 10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives
JP5172124B2 (ja) * 2006-09-29 2013-03-27 関東化学株式会社 ２位に置換基を有する光学活性キヌクリジノール類の製造方法
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
WO2011045648A2 (en) * 2009-10-12 2011-04-21 Matrix Laboratories Limited Process for preparing (s)-(-)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide and its esters thereof
EP2383261B1 (en) 2010-04-23 2013-09-04 Euticals GmbH Process for the asymmetric hydrogenation of ketones
CN102250005B (zh) * 2010-05-19 2015-04-08 浙江九洲药物科技有限公司 艾利西平的制备方法
ES2687678T3 (es) 2011-03-08 2018-10-26 Jubilant Life Sciences Limited Procedimiento para la preparación de (S)-(+)-10,11-dihidro-10-hidroxi-5H-dibenzo[b,f]azepina-5-carboxamida y ésteres de la misma mediante reducción enantioselectiva de 10,11-dihidro-10-oxo-5H-dibenzo[b,f]azepina-5-carboxamida
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
JP2015522531A (ja) 2012-05-07 2015-08-06 セリックスビオ プライヴェート リミテッド 神経筋疾患及び神経変性疾患の治療のための組成物及び方法
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
US9738631B2 (en) 2012-05-07 2017-08-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
AU2013264896A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
IN2015DN02296A (cg-RX-API-DMAC10.html) 2012-09-26 2015-08-21 Ranbaxy Lab Ltd
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
CN103483257A (zh) * 2013-09-06 2014-01-01 江苏同禾药业有限公司 一种亚氨基芪的合成方法
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
CN107207411A (zh) 2014-12-01 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
ES2905771T3 (es) 2015-01-06 2022-04-12 Cellix Bio Private Ltd Composiciones y procedimientos para el tratamiento de la inflamación y del dolor
EP3064490A1 (en) 2015-03-06 2016-09-07 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate
CN107033079B (zh) * 2016-10-17 2020-07-28 扬子江药业集团北京海燕药业有限公司 醋酸艾司利卡西平的制备方法
CN112679433B (zh) * 2019-10-18 2024-05-24 浙江九洲药业股份有限公司 一种艾利西平的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09110836A (ja) * 1995-06-30 1997-04-28 Portela & Co Sa 置換されたジヒドロジベンゾ／ｂ，ｆ／アゼピン、これらの製造方法、幾つかの中枢神経系疾患の治療におけるこれらの使用、及びこれらを含有する薬学的組成物
WO2000076942A1 (fr) * 1999-06-15 2000-12-21 Rhodia Chimie Sulfonylamides et carboxamides et leur application en catalyse asymetrique
WO2002064557A2 (en) * 2001-02-12 2002-08-22 Teva Pharmaceutical Industries Ltd. New crystal forms of oxcarbazepine and processes for their preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09110836A (ja) * 1995-06-30 1997-04-28 Portela & Co Sa 置換されたジヒドロジベンゾ／ｂ，ｆ／アゼピン、これらの製造方法、幾つかの中枢神経系疾患の治療におけるこれらの使用、及びこれらを含有する薬学的組成物
WO2000076942A1 (fr) * 1999-06-15 2000-12-21 Rhodia Chimie Sulfonylamides et carboxamides et leur application en catalyse asymetrique
WO2002064557A2 (en) * 2001-02-12 2002-08-22 Teva Pharmaceutical Industries Ltd. New crystal forms of oxcarbazepine and processes for their preparation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517940A (ja) * 2003-02-17 2006-08-03 ノバルティス アクチエンゲゼルシャフト 神経障害性疼痛におけるｒ−１０−ヒドロキシ−１０，１１−ジヒドロ−カルバマゼピンの使用
JP2016527214A (ja) * 2013-07-01 2016-09-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ケトン類を不斉還元するための新規なルテニウム触媒及びその使用

Also Published As

Publication number Publication date
CA2501237A1 (en) 2004-04-15
HK1079790A1 (zh) 2006-04-13
GB0223224D0 (en) 2002-11-13
PL376379A1 (en) 2005-12-27
TW200413324A (en) 2004-08-01
RU2005114350A (ru) 2006-01-20
US20060142566A1 (en) 2006-06-29
PE20040686A1 (es) 2004-10-29
NO20052244L (no) 2005-07-07
BR0315113A (pt) 2005-08-23
CN101062932A (zh) 2007-10-31
ECSP055738A (es) 2005-07-06
KR20050071549A (ko) 2005-07-07
ZA200502561B (en) 2006-02-22
AU2003276055B2 (en) 2008-01-03
NO20052244D0 (no) 2005-05-06
AU2003276055A1 (en) 2004-04-23
EP1551808A1 (en) 2005-07-13
MXPA05003737A (es) 2005-06-17
AR041544A1 (es) 2005-05-18
CN1703404A (zh) 2005-11-30
WO2004031155A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
AU2003276055B2 (en) Enantioselective process for the preparation of both enantiomers of 10,11-dihydro-10-hydroxy-5H-dibenz [b,f]azepine-5-carboxamide and new crystal forms thereof
JP2007302658A (ja) イマチニブメシレートの多形フォーム及び新規結晶フォーム及び非晶フォーム並びにフォームαの調製方法
KR20110134952A (ko) 카베딜롤 인산염 및(또는) 그의 용매화물, 상응하는 조성물, 및(또는) 치료 방법
RS50600B (sr) Kristalni oblik gama - d ivabradin hlorhidrata, postupak njegove izrade i farmaceutske smeše koje ga sadrže
EP3331889B1 (en) Cyclic compounds useful as modulators of tnf alpha
CN115315418B (zh) 大麻二酚前药及其药物组合物和应用
CN101284812A (zh) 他克林-阿魏酸杂联体,其制备方法及其药物组合物
WO2001072710A1 (en) Heterocycle derivatives and drugs
JP2009209129A (ja) ４−カルバモイル−５−ヒドロキシ−イミダゾール誘導体のスルホン酸塩化合物
JPH10504820A (ja) Ｎ−置換されたフェノチアジン類の使用
KR102768447B1 (ko) (-)-시벤졸린 숙신산염의 신규한 제조 공정
EP0473550A1 (de) Indolonaphthyridine
CN117769547A (zh) 3-芳氧基-3-五元杂芳基-丙胺类化合物的制备方法
KR20120098745A (ko) 치환된 피라졸로피리미딘의 결정질 형태
CN113272315B (zh) 一类类固醇化合物及其用途
JP2010509310A (ja) ３−ベンジル−２−メチル−２，３，３ａ，４，５，６，７，７ａ−オクタヒドロベンゾ［ｄ］イソオキサゾール−４−オンの塩
CN117586204A (zh) 异硒唑酮类化合物、其合成方法及用途
CN120897906A (zh) 制备sstr4激动剂及其盐的方法
JPH11512101A (ja) 新規の抗痙攣作用を有する４位に二置換アミン基を有する１−アリール（アラルキル）−イミダゾリン−２−オンおよびその製法
KR102514961B1 (ko) 에독사반 벤젠술폰산염 1 수화물 결정형 및 그 제조방법
US7595340B2 (en) Serotonin and norepinephrine reuptake inhibitor and uses thereof
JP2002363163A (ja) ベンズアゼピン誘導体
CN101307043A (zh) 6,8-二羟甲基白杨素和6,8-二羟甲基醚白杨素及其制备方法与药物用途
RU2822180C1 (ru) Производные 1,3,4-оксадиазола в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
JP4530853B2 (ja) 抗コレシストキニン活性（抗−ｃｃｋ−１）を有するアントラニル酸誘導体、その製造法および医薬用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100316

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101012